Literature DB >> 25762792

Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future.

Marieke G G Sturkenboom1, Onno W Akkerman2, Mathieu S Bolhuis1, Wiel C M de Lange2, Tjip S van der Werf3, Jan-Willem C Alffenaar4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25762792      PMCID： PMC4356826          DOI： 10.1128/AAC.05173-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

Review 2.  Dried blood spots: a new tool for tuberculosis treatment optimization.

Authors:  D H Vu; J W C Alffenaar; P M Edelbroek; J R B J Brouwers; D R A Uges
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.

Authors:  Julie B Prahl; Isik S Johansen; Arieh S Cohen; Niels Frimodt-Møller; Åse B Andersen
Journal:  J Antimicrob Chemother       Date:  2014-06-16       Impact factor: 5.790

4.  Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin.

Authors:  C Magis-Escurra; H M J Later-Nijland; J W C Alffenaar; J Broeders; D M Burger; R van Crevel; M J Boeree; A R T Donders; R van Altena; T S van der Werf; R E Aarnoutse
Journal:  Int J Antimicrob Agents       Date:  2014-06-09       Impact factor: 5.283

5.  Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  J Antimicrob Chemother       Date:  2014-09-01       Impact factor: 5.790

6.  Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.

Authors:  Tawanda Gumbo; Arnold Louie; Weiguo Liu; David Brown; Paul G Ambrose; Sujata M Bhavnani; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

7.  Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.

Authors:  Ana Requena-Méndez; Geraint Davies; David Waterhouse; Alison Ardrey; Oswaldo Jave; Sonia Llanet López-Romero; Stephen A Ward; David A J Moore
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191
  7 in total
  5 in total

1.  Reply to "adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future".

Authors:  Ana Requena-Méndez; Geraint Davies; David A J Moore
Journal:  Antimicrob Agents Chemother       Date:  2015-04       Impact factor: 5.191

Review 2.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

3.  Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Authors:  Marieke G G Sturkenboom; Leonie W Mulder; Arthur de Jager; Richard van Altena; Rob E Aarnoutse; Wiel C M de Lange; Johannes H Proost; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.

Authors:  Jong Sun Park; Jae-Yeon Lee; Yeon Joo Lee; Se Joong Kim; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Junghan Song; Jae Ho Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

5.  Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania.

Authors:  Andrew Ebers; Suzanne Stroup; Stellah Mpagama; Riziki Kisonga; Isaack Lekule; Jie Liu; Scott Heysell
Journal:  PLoS One       Date:  2017-01-31       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.